Cytokinetics price target raised to $108 from $90 at B. Riley

B. Riley raised the firm’s price target on Cytokinetics (CYTK) to $108 from $90 and keeps a Buy rating on the shares. Recent Myqorzo launch metrics show strong early uptake, with over 50% new patient share among roughly 700 high-volume HCPs by YE26 and formulary parity achieved despite a modest wholesale acquisition cost premium to Camzyos, positioning the product to compete on Risk Evaluation and Mitigation Strategy differentiation rather than price, the analyst tells investors in a research note. Near-term focus is on the Phase 3 ACACIA Non-obstructive Hypertrophic Cardiomyopathy readout expected in early 2Q26, which could drive a halo effect in hypertrophic cardiomyopathy share capture, supported by a higher-dose, faster titration protocol and rigorous patient selection that improve on prior peer trial outcomes, the firm says.